Effective Antitumor of Orally Intestinal Targeting Penetrating Peptide-Loaded Tyroserleutide/PLGA Nanoparticles in Hepatocellular Carcinoma

References

• Bilensoy E. Cationic nanoparticles for cancer therapy. Expert Opin Drug Delivery. 2010;7(7):795–809. doi:10.1517/17425247.2010.485983
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu JQ, et al. Cancer Statistics. CA Cancer J Clin. 2010;60(5):277–300. doi:10.3322/caac.20073
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917. doi:10.1002/ijc.25516
   PubMed Web of Science ®Google Scholar
• Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol. 2011;21(1):59–69. doi:10.1016/j.semcancer.2010.11.002
   PubMed Web of Science ®Google Scholar
• Hernandez-Alvarez MI, Zorzano A. Mitochondrial Dynamics and Liver Cancer. Cancers. 2021;13(11):2571. doi:10.3390/cancers13112571
   PubMedGoogle Scholar
• Lan HY, An P, Liu QP, et al. Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. J Ethnopharmacol. 2021;274:114073. doi:10.1016/j.jep.2021.114073
   PubMed Web of Science ®Google Scholar
• Ruman U, Fakurazi S, Masarudin MJ, et al. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug. Int J Nanomedicine. 2020;15:1437–1456. doi:10.2147/IJN.S236927
   PubMed Web of Science ®Google Scholar
• Yao Z, Che XC, Lu R, et al. Inhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell. Mol Med. 2007;13(1–2):14–21. doi:10.2119/2006-00061.Yao
   PubMedGoogle Scholar
• Che XC, Lu R, Fu Z, et al. Therapeutic effects of tyroserleutide on lung metastasis of human hepatocellular carcinoma SK-HEP-1 and its mechanism affecting ICAM-1 and MMP-2 and −9. Drug Des, Dev Ther. 2018;12:3357–3368. doi:10.2147/DDDT.S177126
   PubMed Web of Science ®Google Scholar
• Lu R, Jia J, Bao L, et al. Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL). Cancer Chemother Pharmacol. 2006;57(2):248–256. doi:10.1007/s00280-005-0046-z
   PubMedGoogle Scholar
• Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: design, evaluation and state-of-the-art. J Control Release. 2016;240:504–526. doi:10.1016/j.jconrel.2016.06.016
   PubMed Web of Science ®Google Scholar
• Plapied L, Duhem N, Des Rieux A, et al. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci. 2011;16(3):228–237. doi:10.1016/j.cocis.2010.12.005
   Web of Science ®Google Scholar
• Shan W, Zhu X, Liu M, et al. Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano. 2015;9(3):2345–2356. doi:10.1021/acsnano.5b00028
   PubMed Web of Science ®Google Scholar
• Kriegel C, Attarwala H, Amiji M. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv Drug Deliv Rev. 2013;65(6):891–901. doi:10.1016/j.addr.2012.11.003
   PubMedGoogle Scholar
• Bakhru SH, Furtado S, Morello AP, et al. Oral Delivery of Proteins by Biodegradable Nanoparticles. Adv Drug Deliv Rev. 2013;65(6):811–821. doi:10.1016/j.addr.2013.04.006
   PubMed Web of Science ®Google Scholar
• Aguirre TAS, Teijeiro-Osorio D, Rosa M, et al. Current Status of Selected Oral Peptide Technologies in Advanced Preclinical Development and in Clinical Trials. Adv Drug Deliv Rev. 2016;106:223–241. doi:10.1016/j.addr.2016.02.004
   PubMed Web of Science ®Google Scholar
• Lonn P, Kacsinta AD, Cui X-S, et al. Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics. Sci Rep. 2016;6(1):32301. doi:10.1038/srep32301
   PubMed Web of Science ®Google Scholar
• Hu X, Fan W, Yu Z, et al. Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery. Nanoscale. 2016;8(13):7024–7035. doi:10.1039/C5NR07474F
   Google Scholar
• Zhang H, Shahbazi MA, Makila EM, et al. Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine. Biomaterials. 2013;34(36):9210–9219. doi:10.1016/j.biomaterials.2013.08.035
   Google Scholar
• Chen MC, Sonaje K, Chen KJ, et al. A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials. 2011;32(36):9826–9838. doi:10.1016/j.biomaterials.2011.08.087
   PubMed Web of Science ®Google Scholar
• Selmin F, Musazzi UM, Magri G, et al. Regulatory aspects and quality controls of polymer-based parenteral long-acting drug products: the challenge of approving copies. Drug Discov Today. 2020;25(2):321–329. doi:10.1016/j.drudis.2019.12.008
   PubMed Web of Science ®Google Scholar
• Boegh M, Nielsen HM. Mucus as a barrier to drug delivery–understanding and mimicking the barrier properties. Basic Clin Pharmacol Toxicol. 2015;116(3):179–186. doi:10.1111/bcpt.12342
   PubMed Web of Science ®Google Scholar
• Li L, Yang L, Li M, et al. A cell-penetrating peptide mediated chitosan nanocarriers for improving intestinal insulin delivery. Carbohyd Polym. 2017;174:182–189. doi:10.1016/j.carbpol.2017.06.061
   PubMed Web of Science ®Google Scholar
• Feger G, Angelov B, Angelova A. Prediction of Amphiphilic Cell-Penetrating Peptide Building Blocks from Protein-Derived Amino Acid Sequences for Engineering of Drug Delivery Nanoassemblies. J Phys Chem B. 2020;124(20):4069–4078. doi:10.1021/acs.jpcb.0c01618
   PubMedGoogle Scholar
• Ye J, Shin MC, Liang Q, et al. 15 years of attempts: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting. J Control Release. 2015;205:58–69. doi:10.1016/j.jconrel.2014.12.002
   PubMed Web of Science ®Google Scholar
• Schmidt N, Mishra A, Lai GH, et al. Arginine-rich cell-penetrating peptides. FEBS Lett. 2010;584(9):1806–1813. doi:10.1016/j.febslet.2009.11.046
   PubMed Web of Science ®Google Scholar
• Nakase I, Takeuchi T, Futaki S. Cell penetrating peptides for chemical biological studies. Methods Mol Biol. 2015;1324:387–396. doi:10.1007/978-1-4939-2806-4_26
   PubMedGoogle Scholar
• Futaki S, Hirose H, Nakase I. Arginine-rich peptides: methods of translocation through biological membranes. Curr Pharm Des. 2013;19(16):2863–2868. doi:10.2174/1381612811319160003
   PubMed Web of Science ®Google Scholar
• Accardo A, Morelli G. Peptide-Targeted Liposomes for Selective Drug Delivery: advantages and Problematic Issues. Biopolymers. 2015;104(5):462–479. doi:10.1002/bip.22678
   PubMed Web of Science ®Google Scholar
• Suma T, Cui JW, Mullner M. Modulated Fragmentation of Proapoptotic Peptide Nanoparticles Regulates Cytotoxicity. J Am Chem Soc. 2017;139(11):4009–4018. doi:10.1021/jacs.6b11302
   PubMedGoogle Scholar
• Liu D, Angelova A, Liu JW, et al. Self-assembly of mitochondria-specific peptide amphiphiles amplifying lung cancer cell death through targeting the VDAC1-hexokinase-II complex. J Mater Chem B. 2019;7(30):4706–4716. doi:10.1039/C9TB00629J
   PubMed Web of Science ®Google Scholar
• Yoo MK, Kang SK, Choi JH, et al. Targeted delivery of chitosan nanoparticles to Peyer’s patch using M cell-homing peptide selected by phage display technique. Biomaterials. 2010;31(30):7738–7747. doi:10.1016/j.biomaterials.2010.06.059
   PubMed Web of Science ®Google Scholar
• Fievez V, Plapied L, Plaideau C, et al. In vitro identification of targeting ligands of human M cells by phage display. Int J Pharm. 2010;394(1–2):35–42. doi:10.1016/j.ijpharm.2010.04.023
   Google Scholar
• Li XL, Liu JY, Lu R, et al. Evaluation of the therapeutic efficacy of tripeptide tyroserleutide (YSL) for human hepatocarcinoma by in vivo hollow fiber assay. Invest New Drugs. 2008;26(6):525–529. doi:10.1007/s10637-008-9121-8
   PubMedGoogle Scholar
• Attene-Ramos MS, Huang RL, Sakamuru S, et al. Systematic Study of Mitochondria Toxicity of Environmental Chemicals Using Quantitative High Throughput Screening. Chem. Res.Toxicol. 2013;26(9):1323–1332. doi:10.1021/tx4001754
   Google Scholar
• Wang DF, Rong WT, Lu Y, et al. TPGS(2k)/PLGA Nanoparticles for Overcoming Multidrug Resistance by Interfering Mitochondria of Human Alveolar Adenocarcinoma Cells. ACS Appl Mater Interfaces. 2015;7:3888–3901. doi:10.1021/am508340m
   PubMed Web of Science ®Google Scholar
• Mittal G, Carswell H, Brett R, et al. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer’s pathology. Controlled Release. 2011;150(2):220–228. doi:10.1016/j.jconrel.2010.11.013
   PubMed Web of Science ®Google Scholar
• Zhang X, Qi J, Lu Y, et al. Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine. 2014;10(1):167–176. doi:10.1016/j.nano.2013.07.011
   PubMed Web of Science ®Google Scholar
• Li MM, Sun YS, Ma CJ, et al. Design and Investigation of Penetrating Mechanism of Octaarginine-Modified Alginate Nanoparticles for Improving Intestinal Insulin Delivery. J Pharm Sci. 2021;110(1):268–279. doi:10.1016/j.xphs.2020.07.004
   PubMed Web of Science ®Google Scholar
• Zhou JL, Chau Y. Different oligoarginine modifications alter endocytic pathways and subcellular trafficking of polymeric nanoparticles. Biomater Sci. 2016;4(10):1462–1472. doi:10.1039/C6BM00371K
   PubMedGoogle Scholar
• Spivak AY, Nedopekina DA, Gubaidullin RR, et al. Conjugation of Natural Triterpenic Acids with Delocalized Lipophilic Cations: selective Targeting Cancer Cell Mitochondria. J Pers Med. 2021;11(6):470. doi:10.3390/jpm11060470
   PubMedGoogle Scholar
• Li L, Geisler I, Chmielewski J, et al. Cationic amphiphilic polyproline helix P11LRR targets intracellular mitochondria. J Control Release. 2010;142:259–266. doi:10.1016/j.jconrel.2009.10.012
   PubMed Web of Science ®Google Scholar
• Maghsoudnia N, Baradaran Eftekhari R, Naderi Sohi A, et al. Mitochondrial delivery of microRNA mimic let-7b to NSCLC cells by PAMAM-based nanoparticles. J Drug Target. 2020;28(7–8):818–830. doi:10.1080/1061186X.2020.1774594
   PubMedGoogle Scholar
• Peng N, Yu H, Yu W, et al. Sequential-targeting nanocarriers with pH-controlled charge reversal for enhanced mitochondria-located photodynamic-immunotherapy of cancer. Acta Biomater. 2020;105:223–238. doi:10.1016/j.actbio.2020.01.005
   PubMedGoogle Scholar
• Feng Y, Qin G, Chang S, et al. Antitumor Effect of Hyperoside Loaded in Charge Reversed and Mitochondria-Targeted Liposomes. Int J Nanomedicine. 2021;16:3073–3089. doi:10.2147/IJN.S297716
   PubMed Web of Science ®Google Scholar
• Zhang Y, Kong X, Li M, et al. The development of a biotin-guided and mitochondria-targeting fluorescent probe for detecting SO2 precisely in cancer cells. Talanta. 2021;225:121992. doi:10.1016/j.talanta.2020.121992
   PubMedGoogle Scholar
• Fang L, Fan H, Guo C, et al. Novel Mitochondrial Targeting Multifunctional Surface Charge-Reversal Polymeric Nanoparticles for Cancer Treatment. J Biomed Nanotechnol. 2019;15(11):2151–2163. doi:10.1166/jbn.2019.2854
   PubMedGoogle Scholar
• Chan KH, Xue B, Robinson RC, et al. Systematic single moiety variations of ultrashort peptides produce profound effects on self-assembly, nanostructure formation, hydrogelation, and phase transition. Sci Rep. 2017;7:12897. doi:10.1038/s41598-017-12694-9
   PubMedGoogle Scholar